Targeted Therapy is the potential and adequate sub-typing is the way
Recent insights into TNBC Subtyping from a comprehensive review on targeted therapy clinical trials. Starting with TNBC subtyping suggested by Lehmann et. al., moving to TNBC patients' phenotypes and their drug response in clinical trials. We managed to suggest an overlap between those subtypes.